Arrhythmias & electrophysiology
Dronedarone Versus Sotalol in Antiarrhythmic Drug–Naive Veterans With Atrial Fibrillation
Authors' conclusion
Dronedarone, compared with sotalol, was associated with a lower risk of ventricular proarrhythmic events and conduction disorders while having no difference in risk of incident cardiovascular hospitalization and mortality.
Study context
- Population
- Antiarrhythmic drug-naive veterans with AF prescribed dronedarone or sotalol in 2012 or later, without conduction disease, pacemaker/ICD, ventricular arrhythmia, cancer, renal failure, liver disease or HFmatched cohort n = 6212
- Participants
- 11,296 veterans
- Exposure
- Dronedarone vs sotalol
- Dronedaronen = 3,106
- Sotaloln = 3,106reference
- Outcome
- CV hospitalization and all-cause mortality
Methodological detailspropensity-score matched, Falsification analyses with nonplausible outcomes were not significant
- Propensity-score matched
- Falsification analyses with nonplausible outcomes were not significant
Main finding
As reported in the abstract
Dronedarone vs SotalolHazard ratio (95% CI)
CV hospitalization
1.03(0.88–1.21)
All-cause mortality
0.89(0.68–1.16)
Observational data: associations, not effects.
Further findings
Mean
| Outcome | Dronedarone | Sotalol |
|---|---|---|
| Baseline LVEF | 55 (SD 11) | 58 (SD 10) |
Safety
| Outcome | HR (95% CI) | |
|---|---|---|
| Ventricular proarrhythmic events and symptomatic bradycardiaDronedaronevs SotalolVentricular proarrhythmic events | 0.53 (0.38–0.74) | |
| Ventricular proarrhythmic events and symptomatic bradycardiaDronedaronevs SotalolSymptomatic bradycardia | 0.56 (0.37–0.87) | |
| 0.20.5125Hazard ratio (log scale) |
Original publication
Dronedarone Versus Sotalol in Antiarrhythmic Drug–Naive Veterans With Atrial Fibrillation. Circ Arrhythm Electrophysiol. Published 24 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →